Your browser does not support iframes.
Teva has a world-leading position in innovative treatments for disorders of the central nervous system (CNS), including neurological and neurodegenerative diseases, pain, and movement disorders, as well as a strong portfolio of products to address respiratory disease, including asthma, allergic rhinitis, and chronic obstructive pulmonary disease (COPD). Across its specialty medicines portfolio, Teva focuses on developing, personalizing and improving treatment of disorders for patients in CNS, respiratory, oncology, and select local/regional therapeutic areas. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.
Our CNS portfolio aims to improve outcomes for patients with a strong emphasis on multiple sclerosis (MS), neurodegenerative disorders and pain management.
Pain affects productivity and quality of life. Our product portfolio for pain brings more relief to patients.